Sagimet Biosciences Inc
SGMT8.410USD
+0.160+1.94%
Market hours （ET）Quotes delayed by 15 min
270.76MMarket Cap
LossP/E TTM
More Details of Sagimet Biosciences Inc Company
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
Company Info
Ticker SymbolSGMT
Company nameSagimet Biosciences Inc
IPO dateJul 14, 2023
CEOMr. David Happel
Number of employees14
Security typeOrdinary Share
Fiscal year-endJul 14
Address155 Bovet Rd., Suite 303
CitySAN MATEO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94402
Phone16505618600
Websitehttps://sagimet.com/
Ticker SymbolSGMT
IPO dateJul 14, 2023
CEOMr. David Happel
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
183.73K
-5.54%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
Mr. Paul W. Hoelscher
Mr. Paul W. Hoelscher
Independent Director
Independent Director
--
--
Mr. Thierry Chauche
Mr. Thierry Chauche
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Elizabeth Grammer, Esq.
Ms. Elizabeth Grammer, Esq.
Independent Director
Independent Director
--
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
183.73K
-5.54%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
KPCB PBD Associates LLC
6.19%
Point72 Asset Management, L.P.
5.72%
AP11 Limited
4.91%
Blue Owl Capital Holdings LP
4.33%
Alyeska Investment Group, L.P.
3.89%
Other
74.96%
Shareholders
Shareholders
Proportion
KPCB PBD Associates LLC
6.19%
Point72 Asset Management, L.P.
5.72%
AP11 Limited
4.91%
Blue Owl Capital Holdings LP
4.33%
Alyeska Investment Group, L.P.
3.89%
Other
74.96%
Shareholder Types
Shareholders
Proportion
Hedge Fund
19.57%
Investment Advisor
14.64%
Corporation
11.58%
Investment Advisor/Hedge Fund
7.50%
Research Firm
2.27%
Individual Investor
1.46%
Pension Fund
0.60%
Bank and Trust
0.10%
Private Equity
0.04%
Other
42.26%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
201
18.06M
58.88%
-8.71M
2025Q1
199
18.50M
63.07%
-6.39M
2024Q4
183
22.20M
72.39%
-4.47M
2024Q3
166
24.34M
79.36%
-2.24M
2024Q2
157
25.83M
85.10%
-301.40K
2024Q1
134
27.23M
89.77%
+13.80M
2023Q4
94
18.02M
81.13%
+2.10M
2023Q3
73
15.74M
73.17%
+13.03M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
KPCB PBD Associates LLC
1.90M
6.19%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.76M
5.72%
-561.43K
-24.24%
Mar 31, 2025
AP11 Limited
1.50M
4.91%
-150.06K
-9.07%
Jun 24, 2025
Blue Owl Capital Holdings LP
1.33M
4.33%
+4.47K
+0.34%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.19M
3.89%
-98.07K
-7.60%
Mar 31, 2025
The Vanguard Group, Inc.
1.15M
3.76%
+22.73K
+2.01%
Mar 31, 2025
Baker Bros. Advisors LP
953.00K
3.11%
--
--
Mar 31, 2025
Rock Springs Capital Management LP
787.81K
2.57%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
724.80K
2.36%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
724.77K
2.36%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
